Corcept Therapeutics Incorporated (0I3Q.L)
0I3Q.L Stock Price Chart
Explore Corcept Therapeutics Incorporated interactive price chart. Choose custom timeframes to analyze 0I3Q.L price movements and trends.
0I3Q.L Company Profile
Discover essential business fundamentals and corporate details for Corcept Therapeutics Incorporated (0I3Q.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
500.00
Website
https://www.corcept.comCEO
Joseph K. Belanoff
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
0I3Q.L Financial Timeline
Browse a chronological timeline of Corcept Therapeutics Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 28 Oct 2025
Upcoming earnings on 28 Jul 2025
Revenue estimate is $199.39M.
Earnings released on 5 May 2025
EPS came in at $0.17 surpassing the estimated $0.14 by +19.30%, while revenue for the quarter reached $157.21M, missing expectations by -27.44%.
Earnings released on 26 Feb 2025
EPS came in at $0.26 falling short of the estimated $0.43 by -39.83%, while revenue for the quarter reached $181.89M, missing expectations by -9.11%.
Earnings released on 31 Oct 2024
EPS came in at $0.41 surpassing the estimated $0.28 by +45.65%, while revenue for the quarter reached $182.55M, beating expectations by +6.15%.
Earnings released on 30 Jul 2024
EPS came in at $0.32 surpassing the estimated $0.23 by +38.70%, while revenue for the quarter reached $163.80M, beating expectations by +5.58%.
Earnings released on 2 May 2024
EPS came in at $0.25 surpassing the estimated $0.22 by +13.77%, while revenue for the quarter reached $146.81M, beating expectations by +3.98%.
Earnings released on 16 Feb 2024
EPS came in at $0.28 surpassing the estimated $0.26 by +8.80%, while revenue for the quarter reached $135.41M, beating expectations by +4.75%.
Earnings released on 2 Nov 2023
EPS came in at $0.28 surpassing the estimated $0.22 by +28.54%, while revenue for the quarter reached $123.60M, beating expectations by +3.25%.
Earnings released on 3 Aug 2023
EPS came in at $0.25 surpassing the estimated $0.15 by +66.40%, while revenue for the quarter reached $117.72M, beating expectations by +7.40%.
Earnings released on 4 May 2023
EPS came in at $0.14 falling short of the estimated $0.20 by -31.07%, while revenue for the quarter reached $105.65M, beating expectations by +0.73%.
Earnings released on 1 Mar 2023
EPS came in at $0.14 falling short of the estimated $0.24 by -40.72%, while revenue for the quarter reached $103.06M, missing expectations by -1.93%.
Earnings released on 30 Sept 2022
EPS came in at $0.30 surpassing the estimated $0.23 by +26.62%, while revenue for the quarter reached $101.73M, missing expectations by -5.43%.
Earnings released on 30 Jun 2022
EPS came in at $0.24 surpassing the estimated $0.24 by +0.34%, while revenue for the quarter reached $103.39M, beating expectations by +2.36%.
Earnings released on 31 Mar 2022
EPS came in at $0.20 falling short of the estimated $0.23 by -14.46%, while revenue for the quarter reached $93.69M, missing expectations by -5.25%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 7 Feb 2022
EPS came in at $0.26 surpassing the estimated $0.23 by +16.36%, while revenue for the quarter reached $98.82M, missing expectations by -1.74%.
Earnings released on 3 Nov 2021
EPS came in at $0.21, while revenue for the quarter reached $91.59M.
Earnings released on 30 Sept 2021
EPS came in at $0.24, while revenue for the quarter reached $96.13M.
Earnings released on 31 Mar 2021
EPS came in at $0.18, while revenue for the quarter reached $79.44M.
Earnings released on 31 Dec 2020
EPS came in at $0.20, while revenue for the quarter reached $85.74M.
Earnings released on 30 Sept 2020
EPS came in at $0.17, while revenue for the quarter reached $86.33M.
0I3Q.L Stock Performance
Access detailed 0I3Q.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.